Clinical trials for Follicular lymphoma
28 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT07128641Odronextamab in Low Tumor Volume Advanced FLGottfried von Keudell, MD PhD · PI: Gottfried Von Keudell, MD, PhD
- RECRUITINGN/ANCT07126678Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular LymphomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGEarly Phase 1NCT06976437A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant TumorsYANRU WANG
- RECRUITINGNCT06794268A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing SettingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company · PI: Bristol-Myers Squibb
- RECRUITINGPhase 1NCT07093073Clinical Study of U01（ssCART-19） in Patients With B-Cell LymphomaShanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd · PI: Wenjun Zhang, Ph.D.
- RECRUITINGPhase 2NCT06959732Zanubrutinib Combined With G-CVP in Previously Untreated FLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- RECRUITINGEarly Phase 1NCT06662227Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell TumorsWondercel Biotech (ShenZhen) · PI: Pengcheng He, M.D. Ph.D.
- RECRUITINGPhase 3NCT06549595A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma PatientsAstraZeneca · PI: Chan Cheah, MBBS FRACP FRCPA DMSc
- RECRUITINGPhase 3NCT06284122Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5The Lymphoma Academic Research Organisation · PI: Franck MORSCHHAUSER
- RECRUITINGNCT06070961Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 MaintenanceFondazione Italiana Linfomi - ETS · PI: Michele Merli, MD
- RECRUITINGPhase 3NCT06091254A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaRegeneron Pharmaceuticals · PI: Clinical Trial Management
- RECRUITINGPhase 2NCT06151080Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FLThe First Affiliated Hospital of Xiamen University · PI: Bing Xu, PhD
- RECRUITINGPhase 2NCT05994235Tazemetostat and Mosunetuzumab in Untreated Follicular LymphomaWeill Medical College of Cornell University · PI: Samuel Yamshon, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT05788081Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.Olivia Newton-John Cancer Research Institute · PI: Eliza Hawkes, MBBS
- RECRUITINGNCT05899621A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FLRuijin Hospital · PI: Weili Zhao
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05749549Phase I/IIa Study of BR1733 in Subjects With Advanced CancersShanghai Blueray Biopharma Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT05643742A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell MalignanciesCRISPR Therapeutics AG · PI: Melanie Allen, M.Sc.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05551936A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular LymphomaVaishalee Kenkre · PI: Vaishalee Kenkre, MD
- RECRUITINGPhase 2NCT04792502Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone LymphomaBrown University · PI: Adam J Olszewski, MD
- RECRUITINGPhase 2NCT05389293A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular LymphomaMemorial Sloan Kettering Cancer Center · PI: Lorenzo Falchi, MD
- RECRUITINGPhase 2NCT04998669Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular LymphomaJuan P. Alderuccio, MD · PI: Juan P Alderuccio, MD
- ACTIVE NOT RECRUITINGNCT05228158A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in JapanEisai Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT04669171A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin LymphomaEnterome · PI: Jan Fagerberg, MD
- RECRUITINGPhase 2NCT04450173Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular LymphomaJoseph Tuscano · PI: Joseph M Tuscano
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03980171Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular LymphomaPeter MacCallum Cancer Centre, Australia
- ACTIVE NOT RECRUITINGNCT03436602Personalized Risk Stratification Model of Follicular Lymphoma PatientsOncology Institute of Southern Switzerland · PI: Davide Rossi, MD, PhD
- RECRUITINGNCT03190928Clonal Evolution in Follicular LymphomaNational Cancer Institute (NCI) · PI: Rahul Lakhotia, M.D.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT01473628Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular LymphomaM.D. Anderson Cancer Center · PI: Bouthaina S Dabaja